Company: SMNR
Filing Date: 2025-04-21
Form Type: S-4/A
Source: 0001193125-25-087342
Chunk: 755

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-21
Form: S-4/A
Chunk 755
---
 accompanying notes to financial statementsF-37
SEMNUR PHARMACEUTICALS, INC. STATEMENTS OF STOCKHOLDERS’ DEFICIT (In thousands, except share amounts)

|                            |     | Common Stock 
 Shares       |             |     | Amount |   |     | Additional 
 Paid-in    
 Capital    |        |     | Accumulated 
 Deficit     |          |   |     | Stockholders’ 
 Deficit       |         |   |
|:---------------------------|:----|:-------------|------------:|:----|:-------|--:|:----|:-----------|-------:|:----|:------------|:---------|:--|:----|:--------------|:--------|:--|
| Balance, December 31, 2022 |     |              | 160,000,000 |     | $      | 2 |     | $          | 72,598 |     | $           | (107,433 | ) |     | $             | (34,833 | ) |
| Net loss                   |     |              |           — |     |        | — |     |            |      — |     |             | (3,261   | ) |     |               | (3,261  | ) |
| Balance, December 31, 2023 |     |              | 160,000,000 |     |        | 2 |     |            | 72,598 |     |             | (110,694 | ) |     |               | (38,094 | ) |
| Net loss                   |     |              |           — |     |        | — |     |            |      — |     |             | (4,690   | ) |     |               | (4,690  | ) |
| Balance, December 31, 2024 |     |              | 160,000,000 |     | $      | 2 |     | $          | 72,598 |     | $           | (115,384 | ) |     | $             | (42,784 | ) |

See accompanying notes to financial statements F-38

#### SEMNUR PHARMACEUTICALS, INC.STATEMENTS OF CASH FLOWS(In thousands)Years Ended December 31,20242023Operating activitiesNet loss$(4,690)$(3,261)Adjustments to reconcile net loss to net cash used for operating activities:Stock-based compensation